FLT3 and acute lymphoblastic leukemia: Early focus areas included “chemotherapy” and “acute lymphoblastic leukemia,” while recent trends highlight “minimal residual disease,” “stem cell transplantation,” and “FLT3,” indicating a shift toward advanced therapies and molecular research.